Rosetta Genomics Reports First Payment From the UK's National Health Service for the Rosetta Cancer Origin Test(TM)

Rosetta Genomics Reports First Payment From the UK's National Health Service 
for the Rosetta Cancer Origin Test(TM) 
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 11/06/13 -- 
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces that the
National Health Service (NHS) of the United Kingdom (UK), the world's
largest publicly-funded health service, has made its first payment to
the Company for use of the Rosetta Cancer Origin Test(TM) on a
British citizen. The accurate identification of the primary tumor
type in primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP) is important in guiding clinician treatment
decisions to maximize patient outcomes.  
John Bridgewater, M.D., University College London Hospital, UCL
Cancer Center, one of the UK's leading experts on CUP and the
patient's treating physician, noted, "Cancers of unknown primary are
a high priority in the UK health system as evidenced by the
requirements to have CUP Clinics at all Cancer Centers. We are very
pleased that the NHS has understood the importance of the Cancer
Origin Test to better define the best therapeutic choices in these
cases, and expect to continue to improve the care of our patients
through utilization of this test." 
"We are very pleased with this payment from the NHS, for although it
does not signify a universal policy decision, it does represent a
pathway for individual patients to gain access to this important test
and shows that the NHS recognizes the clinical value of our Cancer
Origin Test, in conjunction with the treating oncologist's
assessment," stated E. Robert Wassman, M.D., Rosetta's Chief Medical
Officer.  
There are approximately 12,000 new cases of CUP in the UK each year,
representing approximately 5% of all cancer diagnosis. Historically,
nearly all cases are fatal within one year and the median survival is
between three and seven months for an unselected population(1). The
current option of a generic regimen of broadly targeted palliative
chemotherapy is non-specific with correspondingly low response rates
and duration. Multiple chemotherapy regimens have failed to improve
this survival, suggesting that a single regimen approach to this
collective group of heterogeneous cancers is unlikely to be
successful(2-4).  
"Molecular profiling with Rosetta's Cancer Origin Test has
demonstrated clinical validity in identifying cancer origins, which
may provide valuable information for defining more specific treatment
options. We continue to generate clinical data demonstrating improved
outcomes that support the adoption of our microRNA test services in
combination with molecularly-targeted therapies to treat CUP," said
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta
Genomics. "This recent payment by the NHS is another important step
in providing CUP patients in the UK with access to valuable clinical
information that can guide treatment decisions and impact outcomes." 
About Rosetta Cancer Testing Services 
 Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data;
it is the treating physician's responsibility to diagnose and
administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the
Rosetta Cancer Origin Test(TM), 60,000 from the Rosetta Mesothelioma
Test(TM), 65,000 from the Rosetta Kidney Cancer Test(TM) and 226,000
patients from the Rosetta Lung Cancer Test(TM). The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. For more information, please visit
www.rosettagenomics.com. Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309. 
About Rosetta Genomics
 Rosetta develops and commercializes a full
range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited,
CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with
the 2012 North American Next Generation Diagnostics Entrepreneurial
Company of the Year Award. 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test(TM), Rosetta's development or commercialization of molecular
diagnostics, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test(TM), Rosetta's
development of personalized medicine products and services, Rosetta
achieving and maintaining Medicare coverage for its' tests and
Rosetta securing any future payments from international payors,
including NHS, constitute forward-looking statements for the purposes
of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including those risks more fully discussed in the
"Risk Factors" section of Rosetta's Annual Report on Form 20-F for
the year ended December 31, 2012 as filed with the SEC. In addition,
any forward-looking statements represent Rosetta's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless
required by law. 
1. Shaw PH, Adams R, Jordan C, Crosby TD. A clinical review of the
investigation and management of carcinoma of unknown primary in a
single cancer network. Clinical Oncology 2007;19:87-95.
 2. Culine S,
Lortholary A, Voigt JJ, et al. Cisplatin in combination with either
gemcitabine or irinotecan in carcinomas of unknown primary site:
results of a randomized phase II study--trial for the French Study
Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol
2003;21:3479-82.
 3. Gross-Goupil M, Fourcade A, Blot E, et al.
Cisplatin alone or combined with gemcitabine in carcinomas of unknown
primary: Results of the randomised GEFCAPI 02 trial. European Journal
of Cancer 2012;48:721-7.
 4. Hainsworth JD, Spigel DR, Farley C,
Thompson DS, Shipley DL, Greco FA. Phase II Trial of Bevacizumab and
Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl
Cancer Research Network. J Clin Oncol 2007;25:1747-52. 
Company Contact: 
Rosetta Genomics 
Ken Berlin, President & CEO 
(609) 419-9000, ext. 1326 
investors@rosettagenomics.com 
Investor Contacts: 
LHA 
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com 
 
 
Press spacebar to pause and continue. Press esc to stop.